Phase 3
Completed N=36
Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients
Source: ClinicalTrials.gov NCT00127608 ↗Enrolled (actual)
36
Serious AEs
—
Results posted
Feb 2019
Primary outcomePrimary: Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample — 6.49; 6.46; 6.07; 6.02 VZV genome copies per sample
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study is conducted in order to collect clinical samples from patients who are diagnosed of having chickenpox infection. The results of this study will provide basic scientific information about chickenpox disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample |
6.49; 6.46; 6.07; 6.02; 6.98; 6.98 | — |
| PRIMARY Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample by Storage Condition (Dry, Liquid) |
6.34; 6.82 | <0.0001 sig |
| PRIMARY Estimated Mean Viral Load (in log10) by Sample Types (Papule Swab, Vesicle Fluid and Vesicle Swab) |
6.29; 6.74; 6.72 | 0.0038 sig |
Eligibility Criteria
Pediatric patients who are diagnosed of having varicella and are presenting varicella dermal lesions.
Data sourced from ClinicalTrials.gov (NCT00127608). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.